Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits

(Patients with heavily pretreated, late-stage cancer and bone metastasis are usually poor candidates for further chemotherapy. Previously, we showed that association to lipid nanoparticles (LDE) drastically decreases the toxicity of anti-cancer drugs. Here, we tested the hypothesis that paclitaxel (...

Descripción completa

Detalles Bibliográficos
Autores principales: Vital, Carolina G., Maranhão, Raul C., Freitas, Fatima R., Van Eyll, Brigitte M., Graziani, Silvia R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065304/
https://www.ncbi.nlm.nih.gov/pubmed/35517058
http://dx.doi.org/10.1016/j.jbo.2022.100431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065304/
https://www.ncbi.nlm.nih.gov/pubmed/35517058
http://dx.doi.org/10.1016/j.jbo.2022.100431

Ejemplares similares